Clinically isolated syndrome (CIS) is a first episode of neurological symptoms caused by inflammation and damage to the protective coating around nerve fibers in the brain or spinal cord. The episode must last at least 24 hours to qualify as CIS. It’s closely related to multiple sclerosis (MS) and is actually classified as one of the four MS disease courses, but a CIS diagnosis means the episode doesn’t yet meet the full criteria for an MS diagnosis.
What Happens During an Episode
CIS occurs when the immune system attacks myelin, the insulating layer that surrounds nerve cells in the central nervous system. This process, called demyelination, disrupts the electrical signals that travel along nerves. The specific symptoms depend entirely on where in the nervous system the damage occurs.
If the inflammation hits the optic nerve, you might experience blurred vision, eye pain, or partial vision loss in one eye. Damage in the spinal cord can cause numbness, tingling, weakness in the limbs, or problems with balance and coordination. When the brainstem is affected, symptoms can include double vision, dizziness, or difficulty with speech. Some people experience a single symptom in one area (called a monofocal episode), while others develop symptoms pointing to damage in multiple locations at once (a multifocal episode).
These symptoms come on over hours to days and typically improve partially or fully over weeks, though recovery varies from person to person.
How CIS Differs From MS
The key distinction is simple: CIS is a single episode. MS requires evidence that damage has occurred in more than one location in the nervous system and at more than one point in time. Neurologists refer to these two requirements as “dissemination in space” and “dissemination in time.”
Under the 2024 McDonald criteria (the current diagnostic standard), dissemination in space means at least one lesion in two or more of five specific areas: around the brain’s ventricles, at or near the brain’s outer surface, in the lower part of the brain, in the spinal cord, or in the optic nerve. The optic nerve was newly added as a recognized location in the 2024 update. Dissemination in time is established when an MRI shows both older and newer lesions on the same scan, or when a follow-up scan reveals new damage compared to an earlier one.
If someone presents with a first episode and their MRI already shows evidence of both criteria, they skip the CIS label and go straight to an MS diagnosis. CIS is essentially the diagnosis given when the picture is suggestive of MS but incomplete.
One notable change in the 2024 criteria: if a person with a typical clinical presentation has lesions in at least four of the five recognized locations, that alone is now enough for an MS diagnosis, without needing to prove dissemination in time at all.
What Determines Your Risk of Developing MS
Not everyone with CIS goes on to develop MS. Conversion rates reported in research range widely, from 30% to 82%, and the most important factor in estimating your individual risk is what your brain MRI looks like at the time of your first episode.
If your MRI shows lesions typical of demyelination, particularly in areas like the periventricular region (around the brain’s fluid-filled spaces), the corpus callosum, or the cerebellum, your risk is substantially higher. Infratentorial lesions (in the brainstem and cerebellum) may also carry a greater risk of future disability, since those areas control critical functions like movement and coordination. Conversely, if your MRI is completely normal at the time of your first episode, the probability of eventually being diagnosed with MS drops significantly.
A spinal fluid test also provides valuable prognostic information. When cerebrospinal fluid contains oligoclonal bands, which are specific immune proteins not found in the blood, the likelihood of conversion rises sharply. In one study, 93% of CIS patients who later developed MS had tested positive for oligoclonal bands, compared to only 49% of those who did not convert. A newer spinal fluid marker called kappa free light chains can serve the same predictive role and, under the 2024 criteria, is accepted as an alternative to oligoclonal bands.
Tests You Can Expect
After a first neurological episode, the diagnostic workup focuses on two goals: characterizing the current damage and ruling out other explanations for your symptoms.
MRI is the cornerstone. Scans of the brain and spinal cord look for demyelinating lesions and help determine whether dissemination in space and time criteria are already met. A contrast dye injection during the MRI can distinguish between active (enhancing) and older (non-enhancing) lesions, which is critical for establishing whether damage occurred at different time points.
A lumbar puncture (spinal tap) checks for oligoclonal bands and kappa free light chains in the cerebrospinal fluid. These markers indicate an abnormal immune response within the central nervous system and, under current criteria, can substitute for the dissemination-in-time requirement when combined with other findings.
Blood tests are typically ordered to exclude conditions that can mimic CIS. The list of possibilities is broad: autoimmune diseases like lupus and sarcoidosis, vascular problems like small strokes, infections, and a related condition called neuromyelitis optica that requires different treatment. Ruling these out is an essential step before settling on a CIS diagnosis.
Treatment After a First Episode
Whether to start treatment immediately after CIS or wait and monitor is one of the most important decisions you and your neurologist will face. The evidence favors early treatment, particularly if your MRI or spinal fluid results suggest a higher risk of MS.
The BENEFIT trial, one of the longest studies on this question, followed CIS patients for 11 years. Those who started disease-modifying therapy right after their first episode had a 33% lower risk of converting to MS compared to those who waited. They also had a 34.5% lower risk of experiencing a first relapse, and the time to that first relapse was roughly doubled (about five years versus two and a half years). The early-treatment group also performed better on a cognitive processing test over the study period.
Interestingly, by 11 years, disability scores were similarly low in both groups, and MRI findings had evened out. Only about 6% of all participants had progressed to secondary progressive MS. This suggests that while early treatment clearly delays relapses, the long-term disability picture is more nuanced.
Several disease-modifying therapies have been shown to reduce the rate of conversion from CIS to MS. Injectable interferon-based therapies and glatiramer acetate have the strongest evidence. Oral options like teriflunomide and cladribine have also shown benefit, though with slightly less certainty. The choice of medication depends on your risk profile, tolerance for injections versus pills, and side effect considerations.
For people whose MRI is normal and whose spinal fluid tests are negative, the risk of conversion is low enough that careful monitoring with periodic MRIs, rather than immediate medication, is a reasonable approach.
Living With a CIS Diagnosis
A CIS diagnosis places you in a period of uncertainty. You’ve had one episode, and the central question is whether it will remain an isolated event or mark the beginning of MS. This in-between status can be psychologically challenging, and it helps to understand what the monitoring process looks like.
Follow-up MRIs are typically scheduled at intervals to watch for new or enlarging lesions. If new lesions appear, even without new symptoms, your diagnosis may be updated to MS under the current criteria. Any new neurological episode affecting a different part of the nervous system would also fulfill the criteria for MS.
Many people with CIS recover well from their initial episode. Symptoms often improve substantially, though some residual effects like mild numbness or fatigue can linger. Staying connected with a neurologist who specializes in demyelinating diseases ensures that if your diagnosis does change, treatment can begin promptly.